Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 218Rectal Neoplasms 133Stomach Neoplasms 111Colonic Neoplasms 101Pancreatic Neoplasms 81Neoplasm Metastasis 57Esophageal Neoplasms 48Neoplasms 31Adenocarcinoma Of Esophagus 23Adenocarcinoma 21Carcinoma, Hepatocellular 20Carcinoma, Non-Small-Cell Lung 16Biliary Tract Neoplasms 16Gallbladder Neoplasms 15Cholangiocarcinoma 15Gastrointestinal Neoplasms 14Liver Neoplasms 13Lymphoma, Large B-Cell, Diffuse 12Breast Neoplasms 12Unspecified Adult Solid Tumor, Protocol Specific 11Esophageal Squamous Cell Carcinoma 11Bile Duct Neoplasms 10Recurrence 9Peritoneal Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 8Ovarian Neoplasms 8Squamous Cell Carcinoma of Head and Neck 5Head and Neck Neoplasms 5Appendiceal Neoplasms 5Advanced Gastric Cancer 5

Interventions

sirtratumab vedotin 1pembrolizumab 1olaparib 1enfortumab vedotin 1Oxaliplatin 1Nivolumab 1Gemcitabine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Metastatic Urothelial Cancer × Oxaliplatin × Clear all
NCT03451331 2024-05-16

Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

Hoosier Cancer Research Network

Phase 2 Completed
49 enrolled 15 charts
Genitourinary

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡